Literature DB >> 18274715

[Problems in the treatment of upper rectal carcinoma].

T Junginger1, P Hermanek.   

Abstract

In the literature there is some disagreement about the treatment of upper rectal carcinoma (aboral margin 12-16 cm from the anocutaneous line), in particular about the necessary extent of mesorectal excision and the indications for neoadjuvant and adjuvant therapy. The special pathologic features of upper rectal carcinomas (lymphatic spread, distal tumor spread beyond the gross margin) and present clinical experiences are discussed. From it result the following recommendations: partial mesorectal excision, neoadjuvant radiochemotherapy for cT4 tumors only; adjuvant radiochemotherapy in case of intraoperative tumor perforation or incision into/through tumor, incomplete partial mesorectal excision or tumor positive circumferential resection margin (CRM); adjuvant chemotherapy in case of histologically confirmed regional lymph node metastases.

Entities:  

Mesh:

Year:  2008        PMID: 18274715     DOI: 10.1007/s00104-008-1467-0

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  98 in total

1.  Disparate surgical margin lengths of colorectal resection specimens between in vivo and in vitro measurements. The effects of surgical resection and formalin fixation on organ shrinkage.

Authors:  N S Goldstein; A Soman; J Sacksner
Journal:  Am J Clin Pathol       Date:  1999-03       Impact factor: 2.493

2.  Local recurrence after mesorectal excision for rectal cancer.

Authors:  A Nesbakken; K Nygaard; O Westerheim; T Mala; O C Lunde
Journal:  Eur J Surg Oncol       Date:  2002-03       Impact factor: 4.424

3.  Evaluation of a policy of total mesorectal excision for rectal and rectosigmoid cancers.

Authors:  P J Hainsworth; M J Egan; W J Cunliffe
Journal:  Br J Surg       Date:  1997-05       Impact factor: 6.939

4.  Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Medical Research Council Rectal Cancer Working Party.

Authors: 
Journal:  Lancet       Date:  1996-12-14       Impact factor: 79.321

5.  Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer.

Authors:  Jose G Guillem; David B Chessin; Alfred M Cohen; Jinru Shia; Madhu Mazumdar; Warren Enker; Philip B Paty; Martin R Weiser; David Klimstra; Leonard Saltz; Bruce D Minsky; W Douglas Wong
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

6.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

Review 7.  [Rectal carcinoma: is too much neoadjuvant therapy performed? Proposals for a more selective MRI based indication].

Authors:  Th Junginger; P Hermanek; K Oberholzer; H Schmidberger
Journal:  Zentralbl Chir       Date:  2006-08       Impact factor: 0.942

Review 8.  The influence on treatment outcome of structuring rectal cancer care.

Authors:  L Påhlman; U Gunnarsson; U Karlbom
Journal:  Eur J Surg Oncol       Date:  2005-08       Impact factor: 4.424

9.  Total mesorectal excision and local recurrence: a study of tumour spread in the mesorectum distal to rectal cancer.

Authors:  N Scott; P Jackson; T al-Jaberi; M F Dixon; P Quirke; P J Finan
Journal:  Br J Surg       Date:  1995-08       Impact factor: 6.939

10.  Outcome of patients with rectal cancer treated by stapled anterior resection.

Authors:  L Belli; C A Beati; M Frangi; P Aseni; G F Rondinara
Journal:  Br J Surg       Date:  1988-05       Impact factor: 6.939

View more
  5 in total

Review 1.  [Neoadjuvant radiochemotherapy for rectal cancer].

Authors:  W Hohenberger; G Lahmer; R Fietkau; R S Croner; S Merkel; J Göhl; R Sauer
Journal:  Chirurg       Date:  2009-04       Impact factor: 0.955

Review 2.  Is it possible to give a single definition of the rectosigmoid junction?

Authors:  Damien Massalou; David Moszkowicz; Daniela Mariage; Patrick Baqué; Olivier Camuzard; Nicolas Bronsard
Journal:  Surg Radiol Anat       Date:  2017-12-07       Impact factor: 1.246

Review 3.  Required distal mesorectal resection margin in partial mesorectal excision: a systematic review on distal mesorectal spread.

Authors:  A A J Grüter; A S van Lieshout; S E van Oostendorp; J C F Ket; M Tenhagen; F C den Boer; R Hompes; P J Tanis; J B Tuynman
Journal:  Tech Coloproctol       Date:  2022-08-29       Impact factor: 3.699

4.  Adenocarcinomas of the upper third of the rectum and the rectosigmoid junction seem to have similar prognosis as colon cancers even without radiotherapy, SAKK 40/87.

Authors:  S A Käser; J Froelicher; Q Li; S Müller; U Metzger; M Castiglione; U T Laffer; C A Maurer
Journal:  Langenbecks Arch Surg       Date:  2014-08-28       Impact factor: 3.445

5.  Factors Influencing Oncologic Outcomes after Tumor-specific Mesorectal Excision for Rectal Cancer.

Authors:  Kil Yeon Lee
Journal:  J Korean Soc Coloproctol       Date:  2012-04-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.